Certara designed primary research with US payers to understand the rare disease market in three ways:

  • Today’s access landscape
  • Future access landscape with one new product launching
  • Future access landscape with two new products launching
CS rare disease to support commercial decision making 1

Certara designed primary research with US payers to understand the rare disease market

Certara delivered a comprehensive report outlining favorable access for the pipeline product at a price above current standard of care’s wholesale acquisition cost (WAC), and identified endpoints that a second-to-market product could leverage to differentiate from the first-to-market product.

CS rare disease to support commercial decision making 2

お手伝いできることはありませんか?

トップに戻る
Powered by Translations.com GlobalLink OneLink Software